The drug created in the Institute of Cell Therapy, saves lives!
The stem cell based preparation created in the Institute of Cell Therapy opens new opportunities in the treatment of pancreonecrosis.
Pancreatonecrosis is a severe complication of acute pancreatitis (inflammation of the pancreas). The mortality rate for necrotizing pancreatitis makes 40-70%.
The therapy developed by the Institute of Cell Therapy, based on the application of cord blood stem cells, significantly improved the results of treatment of this severe disease.
The novel therapy and drug Pancrostem attracted the attention of a number of foreign orgaisations, including the Parent’s Guide to Cord Blood Foundation, which is the authoritative public organization, promoting awareness of the population about the possibilities of treatment with umbilical cord blood stem cells as well as cord blood preservation.
A new method of treatment of pancreatic necrosis has been tested in a randomized, placebo-controlled clinical studies that lasted three years – from 2008 to 2011. The study involved 179 patients, of which the control group included 106 patients and 73 patients were receiving therapy with Pancrostem.
Pancrostem contains cord blood stem cells.
The results of the study showed that Pancrostem statistically significantly improved the recovery outcomes for patients with pancreatic necrosis and survival rates for this severe disease. The hospital stay of the patients who were appointed Pancrostem, was 1.47-fold shorter compared to the control group, not treated with this medication. The overall mortality rate in the group treated with Pancrostem was 2.06-fold lower compared to control.
Promising results were obtained in patients with necrotizing pancreatitis, treated by stem cells preparation, reducing the frequency of gastrointestinal bleeding. Compared to the control group, this index was 4.71 lower. In 30-50% of patients with pancreatic necrosis pancreatic cysts develop, but in the Pancrostem-treated group the number of such patients was 6.1%. The frequency of postoperative complications in the Pancrostem-treated group was 24.7%, whereas in the control group this index reached 48.1%.
Based on the results of this study, the Ministry of Health of Ukraine in 2012 approved the drug Pancrostem, developed by the Institute of Cell Therapy, as a standard component of the treatment of pancreatic necrosis. In the same year, another stem cell drug, created by the scientists of the Institute of Cell Therapy, was introduced in the standards of treatment of critical limb ischemia. Currently 4 more drugs developed by the Institute of Cell Therapy are being tested in ongoing clinical trials for the treatment of cardiomyopathy, hepatitis, liver cirrhosis and diabetes mellitus type 2.
For more information about the innovative method of treatment of pancreatic necrosis, developed by the specialists of the Institute of Cell Therapy, please visit http://parentsguidecordblood.org/en/news/novel-treatment-pancreonecrosis-using-cord-blood-and-cord-tissue
The acknowledgement of the method of treatment of pancreonecrosis, developed by Ukrainian scientists, by foreign experts once again states about the high level of national investigations in the field of stem cells research and high marketability of the Institute of Cell Therapy.